Source: European Medicines Agency (EU) Revision Year: 2018 Publisher: Aspen Pharma Trading Limited, 3016 Lake Drive Citywest Business Campus, Dublin 24, Ireland
Arixtra 1.5 mg/0.3 ml solution for injection, pre-filled syringe.
Pharmaceutical Form |
---|
Solution for injection. The solution is a clear and colourless liquid. |
Each pre-filled syringe (0.3 ml) contains 1.5 mg of fondaparinux sodium.
Excipient(s) with known effect: Contains less than 1 mmol of sodium (23 mg) per dose, and therefore is essentially sodium free.
For the full list of excipients, see section 6.1.
Active Ingredient | Description | |
---|---|---|
Fondaparinux |
Fondaparinux is a synthetic and selective inhibitor of activated Factor X (Xa). The antithrombotic activity of fondaparinux is the result of antithrombin III (ATIII) mediated selective inhibition of Factor Xa. |
List of Excipients |
---|
Sodium chloride |
Type I glass barrel (1 ml) affixed with a 27 gauge x 12.7 mm needle and stoppered with a bromobutyl or chlorobutyl elastomer plunger stopper.
Arixtra is available in pack sizes of 2, 7, 10 and 20 pre-filled syringes. There are two types of syringes:
Not all pack sizes may be marketed.
Aspen Pharma Trading Limited, 3016 Lake Drive Citywest Business Campus, Dublin 24, Ireland
EU/1/02/206/005-008
EU/1/02/206/024
EU/1/02/206/025
EU/1/02/206/026
Date of first authorisation: 21 March 2002
Date of latest renewal: 21 March 2007
Drug | Countries | |
---|---|---|
ARIXTRA | Austria, Australia, Brazil, Canada, Cyprus, Ecuador, Estonia, Spain, Finland, France, Hong Kong, Croatia, Ireland, Israel, Japan, Lithuania, Mexico, Netherlands, Poland, Romania, Singapore, Turkey, United Kingdom, United States |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.